期刊文献+

V-ATPase a3转运系统影响破骨细胞、骨吸收及骨折愈合的分子机制 被引量:2

Molecular mechanism of osteoclast, bone resorption and fracture healing by V-ATPase a3 transport system
下载PDF
导出
摘要 背景:V-ATPase a3转运系统在破骨细胞对于骨吸收机制中起重要作用。目的:归纳总结V-ATPase a3转运系统在骨折修复中的表达,以及V-ATPase a3转运系统抑制剂对于骨折愈合的影响,进而能更好的指导临床。方法:在国内外期刊数据库中检索近10年内国内外文献,按检索关键词检索相关文献,筛选出符合纳入标准的文献,对其文献进行质量评估后采纳。结果与结论:V-ATPase a3转运系统广泛存在于真核细胞的细胞质膜和细胞器膜上,V-ATPase a3有2个结构域V0和V1,V0结构域是质子转运的通道,V1结构域主要是水解ATP供能。V-ATPase a3转运系统集中存在于破骨细胞皱褶缘上,逆浓度梯度转运H+,为破骨细胞提供酸性环境,溶解无机物,为水解酶创造微环境降解有机物,参与骨吸收。因而V-ATPase a3转运系统在骨折的修复与重塑中选作研究靶点。 BACKGROUND:The V-ATPase a3 transport system plays a crucial role on bone resorption mechanism of the osteoclasts. OBJECTIVE:To observe the expression of V-ATPase a3 transport system in fracture repair and the effect of V-ATPase a3 transport system inhibitor on fracture healing. METHODS:We retrieved related literatures in the periodicals database with the key words, and screen them according to the inclusion criteria. The literatures were included in this study after the evaluation of quality. RESULTS AND CONCLUSION:V-ATPase a3 transport system widely exists in the cytoplasm membrane and organel e membrane of eukaryotic cells. V-ATPase a3 has two structural domains:V0 and V1. V0 structural domain is the proton transport channel, V1 structural domain is mainly the hydrolysis of ATP. V-ATPase a3 transport system focuses on the fril ed edge of osteoclasts, H+is transported to form a high concentration, dissolves inorganic minerals and provides the acidic environment for hydrolytic enzymes, thus being involved in bone resorption. So V-ATPase a3 transport system is selected as the research target in the fracture repair and reshape.
出处 《中国组织工程研究》 CAS CSCD 2014年第20期3257-3262,共6页 Chinese Journal of Tissue Engineering Research
基金 国家自然科学基金(81360554) 吴阶平医学基金会临床科研专项资助基金(320.6750.11061) 甘肃省省青年科技基金计划(1208RJYA066)~~
  • 相关文献

参考文献42

二级参考文献240

共引文献76

同被引文献27

  • 1李敬会,蔡莉莉,李德梅.唑来膦酸治疗老年骨质疏松症临床分析[J].实用老年医学,2013,27(9):777-778. 被引量:13
  • 2NIH Consensus Development Panel on Osteoporosis Pre- vention,Diagnosis and Therapy. Osteoperosis prevention diagnosis and therapy[J~. JAMA, 2001,285 (6) .. 785-795.
  • 3Lee YK, Ha YC, Choi H J, et al. Bisphosphonate use and subsequent hip fracture in South Korea[J]. Osteoporos Int, 2013,24 (11) : 2887-2892.
  • 4Miller PD, Reeker RR, Harris S, et al. Long-term fracture rates seen with continued ibandronate treatment : pooled a- nalysis of DIVA and MOBILE long-term extension stud- ies[J]. Osteoporosis Int, 2014,25 ( 1 ) .. 349-357.
  • 5Ghirardi A,Di Bari M,Zambon A,et al. Effectiveness of oral bisphosphonates for primary prevention of osteoporotic frac- tures[J]. Eur J Clin Pharmacol,2014,70(9) :1129-1137.
  • 6Cotte FE, Fardellone P, Mercier F, et al. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis[J]. Osteoporos Int, 2010,21 ( 1 ) : 145-155.
  • 7Weycker D, Lamerato L, Schooley S, et al. Adherence with bisphosphonate therapy and change in bone mineral densi- ty among women with osteoporosis or osteopenia in clini- cal practice[J]. Osteoporos Int,2013,24(4) ..1483-1489.
  • 8Reid IR, Black DM, Eastell R, et al. Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milli- grams[J]. J Clin Endocrinol Metab,2013,98(2)~557-563.
  • 9Magaziner JS, Orwig DL, Lyles KW, et al. Subgroup varia- tions in bone mineral density response to zoledronic acid after hip fracture[J]. J Bone Miner Res,2014,29 (12) : 2545-2551.
  • 10Sim Iew, Ebeling PR. Treatment of osteoporosis in men with bisphosphonates., rationale and latest evidence[J~. Ther Adv Musculoskelet Dis, 2013,5 (5) : 259-267.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部